{"links":{"html":"https://www.erudio.com/reports/fourlight-1-nct06105632","json":"https://www.erudio.com/reports/fourlight-1-nct06105632.json","markdown":"https://www.erudio.com/reports/fourlight-1-nct06105632.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"fourlight-1-06105632"}},"request":"https://www.erudio.com/contact?report=fourlight-1-06105632"},"offer":{"cited_commentary_sources":35,"verified_hcp_statements":77,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":17,"optional":true,"price_per_verified_person_usd":15,"price_usd":255,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"fourlight-1-nct06105632"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=fourlight-1-06105632","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/fourlight-1-nct06105632","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-23T16:40:39.409111Z","notify_subscribers":false,"status":"new","summary":{"reason":"Initial accepted edition has no weekly change log.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":10,"no_commentary_found":0},"aspects":[{"claim_count":15,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":12,"title":"Primary endpoint: Progression-Free Survival (PFS) progression, as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1"},{"claim_count":6,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":15,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":13,"title":"Population and setting"},{"claim_count":16,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":13,"title":"The comparison"},{"claim_count":15,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":14,"title":"Safety and tolerability"},{"claim_count":8,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":7,"title":"Design and conduct"},{"claim_count":15,"coverage":"discussed","id":"A1","source_count":12,"title":"Continued CDK targeting and treatment sequencing"},{"claim_count":7,"coverage":"discussed","id":"A2","source_count":4,"title":"CDK dependence, resistance mechanisms and biomarker-guided selection"},{"claim_count":8,"coverage":"discussed","id":"A3","source_count":10,"title":"Congress prioritization, brief endorsements and speculative forecasts"},{"claim_count":1,"coverage":"discussed","id":"A4","source_count":1,"title":"Quality-of-life ambition in second-line development"}],"counts":{"cited_sources":35,"claims_by_expression_type":{"comparison":3,"interpretation":13,"opinion":5,"question":10,"restatement":4,"uncertainty":8,"unspecified":34},"claims_by_kind":{"interpretation":4,"limitation":1,"source_observation":72},"clinician_statements":47,"evidence_units":63,"findings":7,"people_cited":13,"people_identity_verified":17,"people_total":24,"screened_sources":61,"verified_claims":77},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":8,"claims_by_group":{"comparisons":2,"experience":0,"questions":4,"restated":0,"views":2},"has_counterview":true,"limitations":3,"links":{"context":2,"support":9},"ma_question":true,"named_voices":6,"passages":9,"sources":6,"sources_by_kind":{"commentary":6}},"title":"Comparator adequacy is the clearest challenge to interpreting the favorable signal"},{"id":"F2","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":0,"questions":5,"restated":4,"views":4},"has_counterview":false,"limitations":4,"links":{"context":0,"support":13},"ma_question":true,"named_voices":8,"passages":8,"sources":8,"sources_by_kind":{"commentary":8}},"title":"Continued CDK targeting is seen as potentially consequential, not proof that resistance has been overcome"},{"id":"F3","structure":{"claims":14,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":6,"views":4},"has_counterview":false,"limitations":4,"links":{"context":1,"support":14},"ma_question":true,"named_voices":12,"passages":13,"sources":12,"sources_by_kind":{"commentary":12}},"title":"Tolerability impressions are favorable, but a comparative marrow-sparing advantage remains an interpretation"},{"id":"F4","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":3,"views":3},"has_counterview":false,"limitations":3,"links":{"context":2,"support":11},"ma_question":true,"named_voices":6,"passages":6,"sources":5,"sources_by_kind":{"commentary":5}},"title":"Patient selection and competing pathways remain open clinical questions"},{"id":"F5","structure":{"claims":15,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":10,"views":2},"has_counterview":false,"limitations":3,"links":{"context":0,"support":15},"ma_question":true,"named_voices":11,"passages":11,"sources":11,"sources_by_kind":{"commentary":11}},"title":"Positive interpretations remain qualified by the stage and completeness of the evidence"},{"id":"F6","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":2},"has_counterview":false,"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":2,"passages":3,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Early development commentary expressed hypotheses and patient-centered aims, not Phase 3 results"},{"id":"F7","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":5,"views":2},"has_counterview":false,"limitations":3,"links":{"context":1,"support":12},"ma_question":false,"named_voices":5,"passages":12,"sources":10,"sources_by_kind":{"commentary":10}},"title":"Congress interest and speculative account posts should not be mistaken for independent HCP agreement"}],"medical_affairs_question":"What does benefit against these control options establish relative to the alternatives clinicians consider after CDK4/6-inhibitor progression?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Comparator choice determines what the favorable signal can establish"},{"id":"section-2","level":2,"title":"Retargeting CDK is an opportunity, not an assertion that resistance is solved"},{"id":"section-3","level":2,"title":"Favorable tolerability impressions do not prove comparative marrow sparing"},{"id":"section-4","level":2,"title":"Selection among another CDK strategy, an ADC and other pathways remains unresolved"},{"id":"section-5","level":2,"title":"Evidence maturity limits how far the positive interpretations can travel"},{"id":"section-6","level":2,"title":"Historical design language and quality-of-life ambitions are not observed results"},{"id":"section-7","level":2,"title":"Attention, anticipation and anonymous forecasts carry different evidentiary weight"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":10}],"id":"T1","label":"Primary endpoint: Progression-Free Survival (PFS) progression, as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":3},{"id":"F5","shared_claims":6}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":6},{"id":"F6","shared_claims":5}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":7},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":7},{"id":"F6","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":13},{"id":"F5","shared_claims":5}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":3},{"id":"F5","shared_claims":4},{"id":"F6","shared_claims":4}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-23T16:40:39.409111Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-23T17:27:33Z","record_hash":"8d57634186ec8102742171dd9944d568319bd254adf39f171ce3cafbb04777d7","release_hash":"eed3c73cb9175646795292ba28aafc521aa97e93de107f02d0b27f55c0555356","report_id":"erudio-nct06105632","run_id":"1929a6e6-2253-4837-91e0-677b57d6fbaf","schema_version":"5.0","slug":"fourlight-1-06105632","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Clinician commentary on FOURLIGHT-1 in the sources reviewed for this edition leads to one open question: What does benefit against these control options establish relative to the alternatives clinicians consider after CDK4/6-inhibitor progression? Its leading findings: (1) comparator adequacy is the clearest challenge to interpreting the favorable signal. (2) continued CDK targeting is seen as potentially consequential, not proof that resistance has been overcome. (3) tolerability impressions are favorable, but a comparative marrow-sparing advantage remains an interpretation. 4 more findings follow. 35 of 61 screened sources are cited; not all HCPs or all public discussion.","meta_description":"61 sources screened · 77 verified statements (47 from speakers with a confirmed clinical role) from 35 sources · 7 findings. Updated Oct 23, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-23T17:27:33Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":61},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","2 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are not a representative sample of HCP opinion. Reposts, quoted posts and repeated announcement summaries cannot be counted as independent agreement.","Discussion that did not name the trial or familiar aliases, or used unusual spellings, may be absent. Some identified passages were not fully assessed for clinician views.","Clinical roles are not stated in the reviewed material for Atsushi Fushimi or Kristina Jankovic. Individual identities and HCP roles are not established for several accounts; their statements remain account-level commentary.","No full protocol or exact-trial results publication was available in the sources reviewed. Detailed methods, subgroup findings and comparative safety interpretations therefore cannot be independently assessed here.","No exact regulatory label for PF-07220060 was available in the reviewed material; this report does not establish an approved use.","Earlier posts reported 264 patients and later abstract-based summaries reported 263. The sources do not explain the difference.","Reports of 6.4% discontinuation and 4.0% treatment-related discontinuation should not be treated as interchangeable or as evidence of improvement over time.","Historical Phase 3 descriptions are preserved as contemporaneous descriptions, not evidence of Phase 3 efficacy or an explanation of the later Phase 2 designation.","Conditional PFS projections and indirect comparisons do not establish observed FOURLIGHT-1 medians or head-to-head rankings.","The ESMO 2026 sources include anticipatory posts and abstract-based commentary. They do not establish the presentation date or every post's timing relative to it, so the edition cannot be characterized as entirely preceding the presentation."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":34,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":35},"count":35,"evidence_window":{"end":"2026-10-23","start":"2024-05-17"},"retrieval_snapshot":"2026-10-23T15:37:44.949703Z","timeline":[{"count":1,"week":"2024-W20"},{"count":1,"week":"2024-W23"},{"count":1,"week":"2024-W25"},{"count":2,"week":"2025-W20"},{"count":13,"week":"2026-W12"},{"count":2,"week":"2026-W13"},{"count":1,"week":"2026-W14"},{"count":1,"week":"2026-W16"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W22"},{"count":2,"week":"2026-W42"},{"count":9,"week":"2026-W43"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06105632:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06105632:context","quote_policy":"short_quote_link_out"},{"id":"openfda:e20d8ca3-8837-4003-8b01-1ebec342062a:20260624","quote_policy":"short_quote_link_out"},{"id":"openfda:5aaf2fb7-93f6-40d6-941a-9583a3794ce7:20260814","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-cgs6uob26ebv2anhmaesngwk-3myelaiv7y62v","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ffhfzwr3igtwt4y7zdompvjv-3mhas67r44x2b","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kwntu4mgap2otpkyzq5bchim-3mhashx4b6y2q","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-smx4mdvydvulspyzksgizf4j-3mhbarsakac27","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-vlbpdban632brzgecx2wjol2-3mhtehjsczb2b","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zqajbwp7dw6i5may4s3qlstb-3mhbascw47d2q","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3mhd6glus5k2l","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3mhich5nsit2p","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3myfcs7mqyj22","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1791378225974677817:b4a76a28-8eac-4276-83c3-4d996ad98b6c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797659272891023614:fe10a4e0-3f1e-45d6-a329-fbc5dd148492","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1922937033544094041:c4f35e6b-8a54-4864-b1b9-0b25fc524d88","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1922950499126456376:74eaf751-b971-423f-8dca-96b8e7fe08ec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1922950619951726870:ce95e83e-6f6e-4a33-a2cc-9118613bac4c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1958959901428138287:5a491bfa-18d5-4ae4-a183-4c4802e5aefb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1986135384573550659:6cd1f412-06df-42af-bf1c-b72938770dc2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2033857794185502807:ffdb1599-8357-4b5c-af9a-4ed213472021","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2033873881803407729:7f361f0c-7a1e-40eb-8083-3c9e55bc92f0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2033874865225158779:0fa657cb-9cf4-4d19-b1eb-6de6f77105cf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2033883654641102949:300e7d81-3c2d-4203-aa7f-dfbf5282e5c1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2033894102589227468:1baca0bf-0f63-46df-8546-7d7178139694","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2033924119637725343:3ace5b3a-7a5a-482d-98e0-26d6581c3690","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2033930752975392787:fda90a54-595c-4f28-90b0-72380eddfcbe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2033955200549990893:5e50cd2d-87c9-4b74-9cab-8d3d6ea21369","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2033974582915277135:a0bc51ec-cd2c-4f27-b76a-0057dfa6c77d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2033979289410888017:151ad7d8-96b2-4300-8678-f153a17440ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2034096639397302557:40d9500d-6ff7-4af0-8390-f329d27e0633","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2034200662859227166:e044038c-8416-4699-9ea2-81e0f3f55bf8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2034232689574785486:87bd8fd4-5db1-4887-9b74-005d9a3cccee","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2034240171605213690:bf5eef36-b8c9-42e0-936b-a77d32528326","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2034646142856941750:181d4960-6ee4-45d9-8679-1c2a26c7013b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2034939302145089580:50982d24-cf47-4d77-b263-c57a0b66161e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2034939912332451968:8341d455-e78d-4a57-8bc6-f36864d16573","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2035218134265954610:f5a4ebec-ea5d-4d79-8b6f-2c94f2dc9c1a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2035458068473843911:b868f5f2-ee39-4193-82f0-21ba7b85095a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037294006317785547:daaf9cd5-4ccd-431a-b115-566565727e41","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037428482045890801:38bb7d99-2083-4700-945f-d15484bbab01","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2038677671589093689:dca86011-8dd7-4aa6-ac2c-216c326fbbce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2045060470072017024:ce2e1ba9-46e1-4fa3-bb77-70db6001f5a4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050371901248409958:417ab3fd-b531-4379-ad7e-32fd7685c077","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2051640084827418864:cab7ff98-d837-456e-a605-c0d870ad2662","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052697331066130543:fefda44c-ec1a-4143-8119-a0aa37c6222c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060667339364761678:a4a71435-0030-44c9-9657-5f7d56c36de8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104229388846076194:0d9d7873-8e3e-4019-bdd6-99a0fe5ad858","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107089120774525204:b7ac3013-7a84-4e43-b87d-844e1f18eb9a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111897988188479542:e7ce78e1-27ee-4e9d-a752-b3677f6e2c29","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111900164373778720:9eaa18ed-6580-4fc9-ad58-8c4cb8bd231f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112144044583424119:8636ed69-5628-4b7d-acd2-e73d88085143","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112483425747636385:60e9d304-63eb-49f0-905b-2d8883160ef1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112487214869295477:d471aeba-b421-409a-bd51-334261878a67","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112802918424510819:9eeab46d-af57-4695-b1fd-eadef264ed06","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112878415535890666:6809ef63-faf7-423b-aab3-e7a379f92f2b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112907173822972062:d45ac167-198d-4c5e-8425-71dd2ebe8be0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112949517620478297:281f5706-6e0c-4a13-8fe6-c89faf16cf6e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112984584279232594:5a96f977-3d2e-4376-908a-6a4970595564","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113000120941965610:bc5411a9-e33b-457b-b1b9-30c0db3efe15","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113016006079889625:b9af0187-92ca-4df3-953d-aa06054ef369","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113200289708736888:b78a46d2-d3de-45e1-8672-96661867e4d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113261592829640762:428fc516-2c4e-4909-b55d-02951e575ed6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113560003898495433:1d42d78f-822d-4537-8781-37359dfbff60","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:BvZYUGWFORY","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":9,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":51,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":61},"count":61,"evidence_window":{"end":"2026-10-23","start":"2024-05-17"},"retrieval_snapshot":"2026-10-23T15:37:44.949703Z","timeline":[{"count":1,"week":"2024-W20"},{"count":1,"week":"2024-W23"},{"count":1,"week":"2024-W25"},{"count":3,"week":"2025-W20"},{"count":1,"week":"2025-W34"},{"count":1,"week":"2025-W45"},{"count":25,"week":"2026-W12"},{"count":3,"week":"2026-W13"},{"count":1,"week":"2026-W14"},{"count":1,"week":"2026-W16"},{"count":1,"week":"2026-W18"},{"count":2,"week":"2026-W19"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W41"},{"count":2,"week":"2026-W42"},{"count":15,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: pf-07220060 cdk4 inhibitor","status":"unmapped"},{"brand_names":["Faslodex"],"label":"fulvestrant","slug":"fulvestrant"},{"brand_names":["Afinitor"],"label":"everolimus","slug":"everolimus"},{"reason":"Unmapped registry intervention: exemestane","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Breast cancer","slug":"breast-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"aliases":["A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 2 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS AT LEAST 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY (FOURLIGHT-1)"],"brief_title":"A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Advanced or Metastatic Breast Cancer"],"enrollment":{"count":333,"type":"ACTUAL"},"interventions":[{"name":"PF-07220060 CDK4 inhibitor","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Fulvestrant","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Everolimus","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Exemestane","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06105632","official_title":"AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 2 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS AT LEAST 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY (FOURLIGHT-1)","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2026-01-12","type":"ACTUAL"},"primary_endpoints":[{"measure":"Progression-Free Survival (PFS) progression, as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1","timeFrame":"From Initiation up to 2 years"}],"registry_last_updated":"2026-08-20","registry_url":"https://clinicaltrials.gov/study/NCT06105632","short_name":"FOURLIGHT-1","short_name_basis":"registry_title","sponsor":"Pfizer","start_date":{"date":"2024-01-09","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2","study_ids":[{"id":"C4391022","type":"sponsor_study_id"},{"domain":"CTIS (EU)","id":"2023-506487-13-00","type":"registry"}],"study_type":"INTERVENTIONAL"}}}